SCTL - Earnings announcements

Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety Candidate CTx-2103 to Deliver a Single Administration of Triple-Release Buspirone KANSAS CITY, Kan., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended September 30, 2022 and provided a clinical and business update. Highlights include

Recorded Q1 Revenue of $21 Million; A 26% Increase Compared to Prior Year Period Signed Multiple New Business Agreements Spanning Early Stage Through Commercial Manufacturing Launching Aseptic Fill-Finish and Lyophilization Service in Q2 2022; Facilities Upgrades Continue Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., May 11, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO" or "Societal"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the first quarte

SAN DIEGO and GAINESVILLE, Ga., May 04, 2022 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. ("Societal CDMO" or "Societal"; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the first quarter 2022 after the market close on Wednesday, May 11, 2022. Societal's management team will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 11, 2022, to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243